GlassScriptPhysician profile
Thomas W Robbins
NPI 1942598305
$5,188.25
in general payments reported to CMS, 2019-2025
36 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $666 · 2021: $865 · 2022: $631 · 2023: $884 · 2024: $689 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $580.81 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $576.76 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $499.39 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Abbvie INC. | $447.51 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.86 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Lilly USA, LLC | $263.67 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $213.58 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $180.85 | 2019-2023 | |
| Welch Allyn | $174.80 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.63 | 2024-2025 | Caplyta |
| Pfizer INC. | $103.80 | 2019-2025 | |
| Medtronic, INC. | $95.61 | 2021-2025 | Minimed 780g |
| Phathom Pharmaceuticals, INC. | $87.70 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $82.97 | 2020-2023 | Xarelto |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.